PL425544A1 - Immunomodulation of cells from myeloid lineage as a therapy - Google Patents

Immunomodulation of cells from myeloid lineage as a therapy

Info

Publication number
PL425544A1
PL425544A1 PL42554418A PL42554418A PL425544A1 PL 425544 A1 PL425544 A1 PL 425544A1 PL 42554418 A PL42554418 A PL 42554418A PL 42554418 A PL42554418 A PL 42554418A PL 425544 A1 PL425544 A1 PL 425544A1
Authority
PL
Poland
Prior art keywords
cells
agonist
myeloid lineage
relates
pharmaceutical composition
Prior art date
Application number
PL42554418A
Other languages
Polish (pl)
Inventor
Zofia Pilch
Tomasz Rygiel
Agata Braniewska
Karolina Tułodziecka
Zuzanna Sas
Marcin Skórzyński
Rafał Pingwara
Original Assignee
Cellis Spolka Z Ograniczona Odpowiedzialnoscia
Univ Warszawski Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellis Spolka Z Ograniczona Odpowiedzialnoscia, Univ Warszawski Medyczny filed Critical Cellis Spolka Z Ograniczona Odpowiedzialnoscia
Priority to PL42554418A priority Critical patent/PL425544A1/en
Publication of PL425544A1 publication Critical patent/PL425544A1/en

Links

Abstract

Niniejsze zgłoszenie dotyczy sposobu zwiększania aktywności przeciwnowotworowej komórek linii mieloidalnej, obejmującego etapy kontaktowania komórek linii mieloidalnej z agonistą receptora Toll-podobnego (TLR) i agonistą receptora determinanty komórkowej 200 (CD200R). Zgłoszenie ponadto dotyczy komórek, które mogą być wytwarzane sposobem i kompozycji farmaceutycznej zawierającej komórki oraz zastosowania tych komórek lub kompozycji farmaceutycznej zawierającej komórki jako leku, a w szczególności do zastosowania w leczeniu nowotworu. Zgłoszenie dotyczy także zestawu obejmującego agonistę TLR i agonistę CD200R. Zgłoszenie dotyczy także kompozycji farmaceutycznej zawierającej agonistę TLR i agonistę CD200R.The present application relates to a method of increasing the anti-tumor activity of cells of the myeloid lineage comprising the steps of contacting the cells of the myeloid lineage with a Toll-like receptor (TLR) agonist and a cell determinant receptor 200 (CD200R) agonist. The application further relates to cells that can be produced by the method and to a pharmaceutical composition containing cells and the use of these cells or a pharmaceutical composition containing cells as a medicament, and in particular for use in the treatment of cancer. The application also relates to a kit comprising a TLR agonist and a CD200R agonist. The application also relates to a pharmaceutical composition comprising a TLR agonist and a CD200R agonist.

PL42554418A 2018-05-15 2018-05-15 Immunomodulation of cells from myeloid lineage as a therapy PL425544A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL42554418A PL425544A1 (en) 2018-05-15 2018-05-15 Immunomodulation of cells from myeloid lineage as a therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL42554418A PL425544A1 (en) 2018-05-15 2018-05-15 Immunomodulation of cells from myeloid lineage as a therapy

Publications (1)

Publication Number Publication Date
PL425544A1 true PL425544A1 (en) 2019-11-18

Family

ID=68536638

Family Applications (1)

Application Number Title Priority Date Filing Date
PL42554418A PL425544A1 (en) 2018-05-15 2018-05-15 Immunomodulation of cells from myeloid lineage as a therapy

Country Status (1)

Country Link
PL (1) PL425544A1 (en)

Similar Documents

Publication Publication Date Title
MX2018015684A (en) Compositions and methods for the depletion of cd117+cells.
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2019008208A (en) Methods of treating cancer with anti-tim-3 antibodies.
WO2019084064A3 (en) Compositions and methods for the depletion of cd117+ cells
MX2020013348A (en) Dll3-cd3 bispecific antibodies.
MX2018015683A (en) Compositions and methods for the depletion of cells.
WO2019084057A3 (en) Compositions and methods for the depletion of cd117+ cells
MX2020013557A (en) A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof.
WO2018157171A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
AU2017238218B2 (en) Early intervention methods to prevent or ameliorate toxicity
MX2019015021A (en) Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies.
WO2019006005A3 (en) Methods and compositions for treating melanoma
MX2018012390A (en) Selenium disulfide compositions for use in treating meibomian gland dysfunction.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
GB201201314D0 (en) Composition
MX2019010382A (en) Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy.
MX2017005134A (en) Treatment of cancer with immune stimulators.
EA201690680A1 (en) COMBINED ANTI-TUMOR TREATMENT WITH THE APPLICATION OF MINICOLES, LOADED BY MEDICINE MEANS, AIMED USING THE BISPECIFIC LIGAND, AND INTERFERON-GAMMA
CR20220329A (en) Anti-mertk antibodies and methods of use thereof
MX2020011254A (en) Anti-bcma car-t-cells for plasma cell depletion.
MX2020012613A (en) Compositions and uses thereof for treating disease or condition.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
CO2020006855A2 (en) Compositions and methods for cd2 + cell depletion
WO2018053264A3 (en) Klrg1 depletion therapy
MX2020005640A (en) Humanized anti-liv1 antibodies for the treatment of breast cancer.